Evidence map›Paper›PMID 33510641›Full record

ArticleFrontiers in pharmacology2020

Characterization of Formononetin Sulfonation in SULT1A3 Overexpressing HKE293 Cells: Involvement of Multidrug Resistance-Associated Protein 4 in Excretion of Sulfate.

Fanye Liu, Shuhua Pei, Wenqi Li, Xiao Wang, Chao Liang, Ruohan Yang, Zhansheng Zhang, Xin Yao, Dong Fang, Songqiang Xie and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Fanye LiuInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Shuhua PeiInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Wenqi LiInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Xiao WangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Chao LiangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Ruohan YangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Zhansheng ZhangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Xin YaoInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Dong FangInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Songqiang XieInstitute of Chemical Biology, School of Pharmacy, Henan University, Kaifeng, China.
Hua SunInstitute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, China.
Henan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formononetin is one of the main active compounds of traditional Chinese herbal medicine

Indexed as

efflux transporterformononetinHEK293 cellsMRP4sulfonation

Identifiers

PMID33510641
PMCPMC7836013
OpenAlexW3120830890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.